Everest Organics hits the roof after securing KDMF nod for Rabeprazole Sodium API
18 - Feb - 2025 12:00 | 41 days ago
The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach, essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux.
According to the regulatory filing, the company revealed that the approval, granted in February 2025, allows it to export its Rabeprazole Sodium API to the South Korean market.
Everest Organics is engaged in the manufacturing of active pharmaceutical ingredients and bulk drugs.
The company's standalone net profit surged to Rs 1.14 crore in Q3 FY25 as against Rs 0.02 crore posted in Q3 FY24. However, revenue from operations fell 19.9% YoY to Rs 42.05 crore in the quarter ended 31 December 2024.
Everest Organics standalone net profit rises 5600.00% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Everest Organics rose 5600.00% to Rs 1.14 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. Sales declined 19.92% to Rs 42.05 crore in the quarter ended December 2024 as against Rs 52.51 crore during the previous quarter ended December 2023.
Everest Organics standalone net profit rises 5600.00% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Everest Organics rose 5600.00% to Rs 1.14 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. Sales declined 19.92% to Rs 42.05 crore in the quarter ended December 2024 as against Rs 52.51 crore during the previous quarter ended December 2023.
Everest Organics hits the roof after securing KDMF nod for Rabeprazole Sodium API
18 - Feb - 2025 12:00 | 41 days ago
The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach, essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux.
According to the regulatory filing, the company revealed that the approval, granted in February 2025, allows it to export its Rabeprazole Sodium API to the South Korean market.
Everest Organics is engaged in the manufacturing of active pharmaceutical ingredients and bulk drugs.
The company's standalone net profit surged to Rs 1.14 crore in Q3 FY25 as against Rs 0.02 crore posted in Q3 FY24. However, revenue from operations fell 19.9% YoY to Rs 42.05 crore in the quarter ended 31 December 2024.
Everest Organics standalone net profit rises 5600.00% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Everest Organics rose 5600.00% to Rs 1.14 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. Sales declined 19.92% to Rs 42.05 crore in the quarter ended December 2024 as against Rs 52.51 crore during the previous quarter ended December 2023.
Everest Organics hits the roof after securing KDMF nod for Rabeprazole Sodium API
18 - Feb - 2025 12:00 | 41 days ago
The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach, essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux.
According to the regulatory filing, the company revealed that the approval, granted in February 2025, allows it to export its Rabeprazole Sodium API to the South Korean market.
Everest Organics is engaged in the manufacturing of active pharmaceutical ingredients and bulk drugs.
The company's standalone net profit surged to Rs 1.14 crore in Q3 FY25 as against Rs 0.02 crore posted in Q3 FY24. However, revenue from operations fell 19.9% YoY to Rs 42.05 crore in the quarter ended 31 December 2024.
Everest Organics standalone net profit rises 5600.00% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Everest Organics rose 5600.00% to Rs 1.14 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. Sales declined 19.92% to Rs 42.05 crore in the quarter ended December 2024 as against Rs 52.51 crore during the previous quarter ended December 2023.
Everest Organics standalone net profit rises 5600.00% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Everest Organics rose 5600.00% to Rs 1.14 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. Sales declined 19.92% to Rs 42.05 crore in the quarter ended December 2024 as against Rs 52.51 crore during the previous quarter ended December 2023.
